Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662673 | 0.81 | ALDH1A1 (0.32) | ALDH1A1TDP1NLRP3 | |
| SCHEMBL15218690 | 0.79 | ALDH1A1 (0.30) | ALDH1A1TDP1NLRP3 | |
| SCHEMBL20654854 | 0.79 | TSHR (0.31) | NLRP3 | |
| SCHEMBL1061645 | 0.77 | — | — | |
| SCHEMBL2006419 | 0.77 | TSHR (0.32) | — | |
| SCHEMBL9662674 | 0.77 | CASP1 (0.32) | — | |
| SCHEMBL204034 | 0.76 | TSHR (0.32) | NLRP3 | |
| SCHEMBL10169834 | 0.74 | — | — | |
| SCHEMBL20211370 | 0.74 | TSHR (0.31) | NLRP3 | |
| Ammonia Solution, Strong SCHEMBL21828798 | 0.74 | TSHR (0.31) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4756863-B2 | — | — | 2011-08-24 | — | — | JP | claimed |
| US-7247720-B2 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-1554300-B1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060069247-A1 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2006-03-30 | — | — | US | claimed |
| EP-1554300-A1 | PHOSPHITYLATION PROCESS | Avecia Biotechnology, Inc. (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2004035599-A1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2004-04-29 | — | — | WO | claimed |
| US-20170015652-A1 | Coumarin-based compounds and related methods | BIOSEARCH TECHNOLOGIES, INC. | 2017-01-19 | — | — | US | disclosed |
| EP-1590361-B1 | PROCESS FOR PURIFYING OLIGONUCLEOTIDE SYNTHONS | NITTO DENKO AVECIA INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-7960542-B2 | Process for purifying oligonucleotide synthons | AVECIA BIOTECHNOLOGY, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1575965-B1 | PROCESS FOR THE PREPARATION OF PHOSPHITYLATION AGENTS | AVECIA BIOTECHNOLOGY INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7560555-B2 | Process for the preparation of phosphitylation agents | AVECIA BIOTECHNOLOGY INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7247720-B2 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1554300-B1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060173187-A1 | Process for the preparation of phosphitylation agents | NITTO DENKO AVECIA, INC. | 2006-08-03 | — | — | US | disclosed |
| US-20060135760-A1 | Process for purifying oligonucleotide synthons | NITTO DENKO AVECIA, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060069247-A1 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2006-03-30 | — | — | US | disclosed |
| EP-1575965-A1 | PROCESS FOR THE PREPARATION OF PHOSPHITYLATION AGENTS | Avecia Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1554300-A1 | PHOSPHITYLATION PROCESS | Avecia Biotechnology, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004055030-A1 | PROCESS FOR THE PREPARATION OF PHOSPHITYLATION AGENTS | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004035599-A1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135760-A1 | Process for purifying oligonucleotide synthons | NUDT1, POLN, POLRMT | ALDH1A1 4643/4885TDP1 1684/4885NLRP3 4231/4885 |
| US-20170015652-A1 | Coumarin-based compounds and related methods | HCCS, FBL, COIL | ALDH1A1 990/4885TDP1 958/4885NLRP3 2313/4885 |
| US-20060069247-A1 | Phosphitylation process | PHOSPHO1, MTAP, PNP | ALDH1A1 2571/4885TDP1 919/4885NLRP3 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.